Government Programs	6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Government Programs	Government Programs Research and Development Tax Incentive The Company recognized AUD 501,000 ($377,000) and AUD 635,000 ($480,000) as a reduction of research and development expenses for the three and six months ended June 30, 2017, respectively, in connection with the research and development tax incentive from Australia. The Company recognized AUD 666,000 ($498,000) and AUD 1.4 million ($1.0 million) as a reduction of research and development expenses for the three and six months ended June 30, 2016, respectively, in connection with the research and development tax incentive from Australia. As of June 30, 2017, and December 31, 2016, the research and development tax incentive receivable was AUD 3.7 million ($2.9 million) and AUD 3.1 million ($2.2 million), respectively. In March 2016, the Company received AUD 237,000 ($181,000) for overseas findings and recorded the funds as deferred tax incentive in accrued expenses and other payables on the condensed consolidated balance sheet due to the possibility that the funds could have to be repaid. In December 2016, the Company’s research and development project under the AusIndustry research and development tax incentive program was complete and the Company substantiated that more than 50% of the total project expenditures occurred in Australia. Therefore, the overseas finding related incentive amounts were no longer deemed to be at risk of clawback and the Company recognized such amounts in December 2016 as a reduction of research and development expenses for the overseas findings received in 2016. SBIR Grant In May 2017, the Company was awarded a Phase 2 Small Business Innovation Research ("SBIR") Grant from the National Institute of Diabetes and Digestive and Kidney Diseases ("NIDDK") of the National Institutes of Health ("NIH") in support of research aimed at developing biomarkers that define IL-23R target engagement by oral peptide antagonists and the effects of that engagement of downstream signaling. The total grant award was $1.3 million and is for the period from May 2017 to April 2019. In July 2016, the Company was awarded a Phase 1 SBIR Grant from the National Institute of Heart and Lung Diseases of the NIH in support of pre-clinical research aimed at discovering and optimizing lead molecules as novel peptide mimetics of the natural hepcidin hormone. The total grant award was $219,000 and was for the period from August 2016 to January 2017. In September 2015, the Company was awarded a Phase 1 SBIR Grant from the NIDDK of the NIH in support of research on orally stable peptide antagonists of IL-23R as potential treatments for IBD. The total grant award was $224,000 and was for the period from September 2015 to August 2016. The Company recognizes a reduction to research and development expenses when expenses related to the grants have been incurred and the grant funds become contractually due from NIH. The Company recorded $20,000 as a reduction of research and development expenses for the three and six months ended June 30, 2017. The Company recorded $69,000 as a reduction of research and development expenses for the six months ended June 30, 2016. The Company recorded a receivable for $19,000 and $100,000 as of June 30, 2017 and December 31, 2016, respectively, to reflect the eligible costs incurred under the grants that are contractually due to the Company and such amounts are included in the prepaid expenses and other current assets on the condensed consolidated balance sheets.

Government Programs

Research and Development Tax Incentive

The Company recognized AUD 501,000 ($377,000) and AUD 635,000 ($480,000) as a reduction of research and development expenses for the three and six months ended June 30, 2017, respectively, in connection with the research and development tax incentive from Australia. The Company recognized AUD 666,000 ($498,000) and AUD 1.4 million ($1.0 million) as a reduction of research and development expenses for the three and six months ended June 30, 2016, respectively, in connection with the research and development tax incentive from Australia. As of June 30, 2017, and December 31, 2016, the research and development tax incentive receivable was AUD 3.7 million ($2.9 million) and AUD 3.1 million ($2.2 million), respectively.

In March 2016, the Company received AUD 237,000 ($181,000) for overseas findings and recorded the funds as deferred tax incentive in accrued expenses and other payables on the condensed consolidated balance sheet due to the possibility that the funds could have to be repaid. In December 2016, the Company’s research and development project under the AusIndustry research and development tax incentive program was complete and the Company substantiated that more than 50% of the total project expenditures occurred in Australia. Therefore, the overseas finding related incentive amounts were no longer deemed to be at risk of clawback and the Company recognized such amounts in December 2016 as a reduction of research and development expenses for the overseas findings received in 2016.

SBIR Grant

In May 2017, the Company was awarded a Phase 2 Small Business Innovation Research ("SBIR") Grant from the National Institute of Diabetes and Digestive and Kidney Diseases ("NIDDK") of the National Institutes of Health ("NIH") in support of research aimed at developing biomarkers that define IL-23R target engagement by oral peptide antagonists and the effects of that engagement of downstream signaling. The total grant award was $1.3 million and is for the period from May 2017 to April 2019.

In July 2016, the Company was awarded a Phase 1 SBIR Grant from the National Institute of Heart and Lung Diseases of the NIH in support of pre-clinical research aimed at discovering and optimizing lead molecules as novel peptide mimetics of the natural hepcidin hormone. The total grant award was $219,000 and was for the period from August 2016 to January 2017.

In September 2015, the Company was awarded a Phase 1 SBIR Grant from the NIDDK of the NIH in support of research on orally stable peptide antagonists of IL-23R as potential treatments for IBD. The total grant award was $224,000 and was for the period from September 2015 to August 2016.

The Company recognizes a reduction to research and development expenses when expenses related to the grants have been incurred and the grant funds become contractually due from NIH. The Company recorded $20,000 as a reduction of research and development expenses for the three and six months ended June 30, 2017. The Company recorded $69,000 as a reduction of research and development expenses for the six months ended June 30, 2016. The Company recorded a receivable for $19,000 and $100,000 as of June 30, 2017 and December 31, 2016, respectively, to reflect the eligible costs incurred under the grants that are contractually due to the Company and such amounts are included in the prepaid expenses and other current assets on the condensed consolidated balance sheets.